Neocitec (Vinorelbine)

Vinorelbine is used in oncology to target rapidly dividing tumor cells in specific cancer types.

• Non‑small cell lung cancer: improves disease control and may extend survival in advanced cases.
• Breast cancer (early or metastatic): used in combination regimens to reduce tumor burden and delay progression.
• Metastatic breast cancer: provides palliation and contributes to overall response rates when combined with other chemotherapeutics.

• Vinorelbine binds to tubulin, inhibiting microtubule polymerisation during the M-phase of the cell cycle. This disruption prevents proper spindle formation, leading to cell‑cycle arrest and apoptosis of rapidly dividing cancer cells, thereby reducing tumor proliferation.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced white blood cell count increasing infection risk.
• Nausea and vomiting: gastrointestinal upset common after infusion.
• Fatigue: persistent tiredness affecting daily activities.
• Constipation: decreased bowel movements.
• Alopecia: hair thinning or loss.
• Mild peripheral neuropathy: tingling sensations in extremities.

Serious or Rare Side Effects

• Severe neutropenia with fever (febrile neutropenia).
• Pulmonary toxicity: interstitial pneumonitis or fibrosis.
• Anaphylactic reactions: sudden severe allergic response.
• Cardiac toxicity: arrhythmias or decreased cardiac function.
• Severe hypotension: sudden drop in blood pressure during infusion.

Vinorelbine requires careful monitoring and specific safety measures before and during therapy.

• Monitor blood counts: perform regular CBC to detect neutropenia early.
• Assess liver function: adjust dosing in patients with hepatic impairment.
• Evaluate pulmonary status: use caution in patients with pre‑existing lung disease.
• Avoid concurrent myelosuppressive agents: reduces risk of severe bone‑marrow suppression.
• Adjust for renal impairment: consider dose modification in reduced kidney function.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase vinorelbine exposure and toxicity.
• Concurrent myelosuppressive chemotherapy agents: heighten risk of severe neutropenia.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug levels, decreasing effectiveness.
• Anticoagulants (e.g., warfarin): increased bleeding risk, monitor coagulation parameters.
• Live vaccines: immunosuppression may diminish vaccine efficacy, avoid during treatment.